How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

467 results for

High Altitude Edema

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Myths and Realities: Airline Travel and Deep Venous Thrombosis-Does Economy Class Syndrome Really Exist?

and venous thrombosis in long flights with elastic stockings. A randomized trial: The LONFLIT 4 Concorde Edema-SSL Study. Angiology. 2002;53:635-645. . 9. Cesarone M.R. Venous thrombosis from air travel: the LONFLIT 3 study – prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53:1-6. . 10. Lapostolle, F. Severe pulmonary embolism associated with air travel. New Eng J Med. 2001;345:779-783. . 11. Landgraf, H. Economy class syndrome (...) of the general population, all travelers departing on prolonged flights are – at a minimum – predisposed to increased periods of blood flow stasis secondary to prolonged cramped seating, possible dehydration, and hypobaric hypoxia. These conditions, in addition to passenger-specific conditions (obesity, age, inherited thrombophilias etc.), account for the roughly three-fold higher incidence of VTE in non-high risk patients [5]. Blood flow stasis and subsequent coagulation activation have been known to stem

2014 Clinical Correlations

162. Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3,450 m. (PubMed)

Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3,450 m. Remote ischemic preconditioning (RIPC) has been shown to protect remote organs, such as the brain and the lung, from damage induced by subsequent hypoxia or ischemia. Acute mountain sickness (AMS) is a syndrome of nonspecific neurologic symptoms and in high-altitude pulmonary edema excessive hypoxic pulmonary vasoconstriction (HPV) plays a pivotal role. We hypothesized that RIPC protects (...) h and stayed there for 48 h. AMS was evaluated by the Lake Louise score (LLS) and the AMS-C score. Systolic pulmonary artery pressure (SPAP) was assessed by transthoracic Doppler echocardiography. RIPC had no effect on the overall incidence (RIPC: 35%, control: 35%, P = 1.0) and severity (RIPC vs.P = 0.496 for LLS; P = 0.320 for AMS-C score) of AMS. RIPC also had no significant effect on SPAP [maximum after 10 h at high altitude; RIPC: 33 (SD 8) mmHg; controls: 37 (SD 7) mmHg; P = 0.19

2018 Journal of applied physiology (Bethesda, Md. : 1985)

163. Substrate stiffness-dependent exacerbation of endothelial permeability and inflammation: mechanisms and potential implications in ALI and PH (2017 Grover Conference Series) (Full text)

Substrate stiffness-dependent exacerbation of endothelial permeability and inflammation: mechanisms and potential implications in ALI and PH (2017 Grover Conference Series) The maintenance of endothelial barrier integrity is absolutely essential to prevent the vascular leak associated with pneumonia, pulmonary edema resulting from inhalation of toxins, acute elevation to high altitude, traumatic and septic lung injury, acute lung injury (ALI), and its life-threatening complication, acute

2018 Pulmonary circulation PubMed

164. T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent

Drug: T89 225 mg group Drug: Placebo Drug: T89 300 mg group Phase 2 Detailed Description: Acute mountain sickness (AMS) is a common ailment in people venturing over 2500 meters altitude. It is a pathological effect of high altitude on humans, caused by acute exposure to low partial pressure of oxygen at high altitude. It presents as a collection of nonspecific symptoms, acquired at high altitude or in low air pressure, including headache and one of the following: gastrointestinal symptoms, fatigue (...) and/or weakness, dizziness/ lightheadedness or difficulty sleeping. Severity and incidence of these conditions depend on the rate of ascent, elevation obtained, duration of altitude exposure, physical exertion, and inherent genetic susceptibility. Pilgrims to high altitudes are at an added risk since they are unaware and they gain height faster than the recommendations. The underlying pathophysiology of AMS remains poorly defined, but some data support the role of increased fluid retention, which may

2018 Clinical Trials

165. Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo)

condition, on the same medication for > 4 weeks Patient live permanently at an altitude < 1000m asl. Exclusion Criteria: Resting partial Oxygen pressure (PaO2) ≤7.3 kilopascal (kPA) corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, high-altitude pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure (...) Sponsor: University of Zurich Information provided by (Responsible Party): University of Zurich Study Details Study Description Go to Brief Summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart function (Echo). Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude (FiO2: 15.1

2018 Clinical Trials

166. Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise

related diseases (AMS, high-altitude pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation Residence > 1000m above sea level Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with Walking disability Women who are pregnant or breast feeding Contacts and Locations Go to Information (...) (PAWP) ≤15 mmHg during right heart catheterization at the time of Initial diagnosis PH class 1 (PAH) or 4 (CTEPH) Stable condition, on the same medication for > 4 weeks Patient live permanently at an altitude < 1000m asl. Exclusion Criteria: Resting partial oxygen pressure (PaO2) ≤7.3 kilopascal (kPA) corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude

2018 Clinical Trials

167. Acute Exposure of Simulated Hypoxia on Cognitive Function

(nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, high-altitude pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation Residence > 1000m above sea level Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic (...) Description Go to Brief Summary: Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on cognitive functions. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude (FiO2: 15.1%) Device: Shamed Hypoxia (FiO2: 20.9) Not Applicable Detailed Description: Low altitude baseline measurements will be performed in Zurich (460m asl) including

2018 Clinical Trials

168. Acute Exposure of Simulated Hypoxia on Blood and Tissue Oxygenation (aBGA, NIRS)

daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, high-altitude pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation Residence > 1000m above sea level Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability Women who (...) provided by (Responsible Party): University of Zurich Study Details Study Description Go to Brief Summary: Randomized crossover trial in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on blood and tissue oxygenation (ABGA, near infrared spectroscopy) Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated

2018 Clinical Trials

169. Acute Exposure of Simulated Hypoxia on Heart Rate and Ventilation During Exercise

for > 4 weeks Patient live permanently at an altitude < 1000m asl. Exclusion Criteria: Resting partial oxygen pressure (PaO2) ≤7.3 kilopascal (kPA) corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, high-altitude pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 (...) provided by (Responsible Party): University of Zurich Study Details Study Description Go to Brief Summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on heart rate and Ventilation changes under exercise. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude: (FiO2: 15.1) Device: Shamed Hypoxia (FiO2: 20.9

2018 Clinical Trials

170. Acute Exposure to Simulated Hypoxia on Exercise Capacity

to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, High Altitude Pulmonary edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation Residence > 1000m above sea level Inability to follow the procedures of the study, e.g. due to language problems (...) Description Go to Brief Summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) in constant loaded exercise capacity. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude (FiO2: 15.1%) Device: Shamed Hypoxia (FiO2: 20.9) Not Applicable Detailed Description: Low altitude baseline measurements will be performed in Zurich (460m asl

2018 Clinical Trials

171. Acute Exposure of Simulated Hypoxia on Cardiac Output

at an altitude < 1000m asl. Exclusion Criteria: Resting partial oxygen pressure (PaO2) ≤7.3 kiloPascal (kPA) corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed) Severe daytime hypercapnia (pCO2 > 6.5 kPa) Susceptibility to high altitude related diseases (AMS, High Altitude Pulmonary Edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study (...) by (Responsible Party): University of Zurich Study Details Study Description Go to Brief Summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on non-invasive cardiac output assessments by Finapres® "NOVA" Technology at rest and under exercise. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude (FiO2: 15.1) Device: Shamed

2018 Clinical Trials

172. Effects of Pneumatic Vitreolysis on Vitreomacular Traction

one eye meets the study eye criteria listed below. Able and willing to provide informed consent. Able and willing to avoid high altitude travel, including airline travel, until gas resolution (approximately 6 to 8 weeks). For phakic patients, able and willing to avoid supine position until gas resolution (approximately 6 to 8 weeks). Able and willing to wear wristband that informs any medical personnel that the patient has a gas bubble in the eye Exclusion A potential participant is not eligible (...) visual acuity remains stable • An eye that requires prompt treatment for VMT should not be enrolled Exclusion e. Other ocular condition that might affect visual acuity during the course of the study or require intraocular treatment (e.g., retinal vein occlusion, substantial age-related macular degeneration, or macular edema induced by a condition other than VMT) • If diabetic retinopathy is present, severity level must be microaneurysms only or better (≤ diabetic retinopathy severity level 20

2018 Clinical Trials

173. Acute Exposure of Simulated Hypoxia on ECG and Non-invasive Blood Pressure

> 6.5 kPa) Susceptibility to high altitude related diseases (AMS, High Altitude Pulmonary Edema (HAPE), etc.) based on previous experienced discomfort at altitudes. Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation Residence > 1000m above sea level Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability Women who are pregnant or breast feeding (...) Party): University of Zurich Study Details Study Description Go to Brief Summary: Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by Finapres® NOVA Technology. Condition or disease Intervention/treatment Phase Pulmonary Hypertension Device: Simulated Altitude: (FiO2: 15.1) Device: Shamed Hypoxia

2018 Clinical Trials

174. Effects of Pneumatic Vitreolysis on Macular Hole

inclusion criteria must be met: Age ≥ 18 years • Participants < 18 years old are not being included because the condition is so rare in this age group that the diagnosis may be questionable. At least one eye meets the study eye criteria Able and willing to provide informed consent Able and willing to avoid high altitude travel, including airline travel, until gas resolution (approximately 6 to 8 weeks) For phakic patients, able and willing to avoid supine position until gas resolution (approximately 6 (...) ) Exclusion Other ocular condition that might affect visual acuity during the course of the study or require intraocular treatment (e.g., retinal vein occlusion, substantial age-related macular degeneration, or macular edema induced by a condition other than VMT) If diabetic retinopathy is present, severity level must be microaneurysms only or better (≤ diabetic retinopathy severity level 20). Presence of drusen is acceptable; however, eyes with geographic atrophy or neovascular age-related macular

2018 Clinical Trials

175. The effects of respiratory inhaled drugs on the prevention of acute mountain sickness. (Full text)

The effects of respiratory inhaled drugs on the prevention of acute mountain sickness. Acute mountain sickness (AMS) is common in high-altitude travelers, and may lead to life-threatening high-altitude cerebral edema (HACE) or high-altitude pulmonary edema (HAPE). The inhaled drugs have a much lower peak serum concentrations and a shorter half-life period than oral drugs, which give them a special character, greater local effects in the lung. Meanwhile, short-term administration of inhaled (...)  ± 0.89 vs 1.91 ± 1.23, P < .05) and BUD (1.35 ± 0.94 vs 1.91 ± 1.23, P < .05) groups were both significantly lower than the placebo group at 72 hours. There were no significant differences in LLS scores among the 4 groups at 120 hours. The incidence of AMS in the COM group was significantly reduced at 72 hours (16.7% in COM group vs 43.4% in placebo group, P < .05) after exposure to high-altitude. There were no significant differences in AMS incidences at 120 hours among the 4 groups.The prophylactic

2018 Medicine PubMed

176. Comparison of Optic Nerve Sheath Diameter between both eyes: A Bedside Ultrasonography Approach (Full text)

by bedside ocular ultrasonography (USG) in Indian adults.This was a prospective study conducted from September 2012 to March 2013 in the Department of Internal Medicine of a tertiary care hospital situated at moderate high altitude (11,500 ft) in India.Patients admitted with high altitude pulmonary edema (HAPE) were recruited by convenience sampling. The ONSD of both eyes were measured 3 mm behind the globe using a 7.5 MHz linear probe on the closed eyelids of supine subjects.Analysis was done using SPSS

2018 Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine PubMed

177. Family Practice Notebook Updates 2018

loose wound closure If closing a potentially contaminated wound, choose either primary closure or by second intention (ob, bleed) Painless after 18-20 weeks is until proven otherwise (surgery, procedure) High volume >5 liters may result in significant , , pulmonary edema (surgery, procedure) Bleeding after implant placement may occur in the first 24 hours requiring return to surgery V. Updates: September 2018 (hemeonc, cancer, bone, ) s include , , and much less common, is most common, affects age 5 (...) altitude with cabins pressurized to 7000 feet (urology, sx) May be due to instrumentation (cystoscopy), fistula from bowel or vagina, renal tumor infarction, urinary diversion or with p-valve However, it is critical to exclude UTI with gas forming organisms (e.g. , , , Candida, ) UTI with gas forming organisms may result in or which are associated with high mortality Staghorn calculi and low may indicate the presence of gas forming organisms (surgery, gi) The classic triad of or back pain

2019 FP Notebook

178. Stress Echo 2020

at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70). Procedure: B-lines SE SE will be performed with special focus on lung sonography and B-lines (...) , multicenter, international, observational study design, > 100 certified high-volume SE labs will be networked with an organized system of clinical, laboratory and imaging data collection at the time of physical or pharmacological SE, with structured follow-up information. The study is endorsed by the Italian Society of Echocardiography and organized in 10 subprojects focusing on: contractile reserve for prediction of cardiac resynchronization or medical therapy response; stress B-lines in heart failure

2017 Clinical Trials

179. Association between regulator of telomere elongation helicase1 (RTEL1) gene and HAPE risk: A case-control study. (Full text)

Association between regulator of telomere elongation helicase1 (RTEL1) gene and HAPE risk: A case-control study. High altitude pulmonary edema (HAPE) is a paradigm of pulmonary edema. Mutations in regulator of telomere elongation helicase1 (RTEL1) represent an important contributor to risk for pulmonary fibrosis. However, little information is found about the association between RTEL1 and HAPE risk. The present study was undertaken to tentatively explore the potential relation between single

2017 Medicine PubMed

180. Corydalis hendersonii Hemsl. protects against myocardial injury by attenuating inflammation and fibrosis via NF-κB and JAK2-STAT3 signaling pathways. (PubMed)

Corydalis hendersonii Hemsl. protects against myocardial injury by attenuating inflammation and fibrosis via NF-κB and JAK2-STAT3 signaling pathways. Corydalis hendersonii Hemsl. (CH) with heat clearing and detoxifying effects are well described in Tibetan folk medicine. It has been used for centuries in China largely for the treatment of high altitude polycythemia, a pathophysiological condition referred to "plethora" in Tibetan medicine, hypertension, hepatitis, edema, gastritis, and other

2017 Journal of Ethnopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>